Antibiotic liposomal formulations for improving Respiratory health in cystic fibrosis: A review on Trends in liposomal research

Sagar, Rashmi Mathews, Beny Baby, S.Rajarajan, Praghna M R and K.Ramesh

Cystic fibrosis results in defective mucociliary clearance together with persistent pulmonary infections mostly due to Pseudomonas aeruginosa. The effectiveness of conventional antibiotics remains limited because they clear rapidly from the body and bacteria develop growing resistance patterns. Liposomal antibiotics enable better pulmonary tissue retention along with more precise drug distribution and fewer required medication doses. Using Arikayce, LipoBiEDT-TOB™ and Pulmaquin™ has shown potential for treating cystic fibrosis. Better therapeutic outcomes will be achieved through future developments in PEGylated along with stimuli-responsive and gene-integrated liposomal systems.

Keywords – Cystic fibrosis, liposomes, antibiotic resistance, pulmonary drug delivery, Pseudomonas aeruginosa, Arikayce, PEGylation, Nano medicine.